Lantheus' Pylarify Hit $1B in 2024 Sales

Core Insights - Lantheus Holdings reported significant achievements in its radiopharmaceutical portfolio, particularly with the success of Pylarify, and announced two strategic acquisitions aimed at enhancing growth and capabilities [1][3][6] Sales Performance - Pylarify has achieved over $1 billion in sales for 2024, marking it as the first radiodiagnostic blockbuster, with fourth-quarter sales reaching $266 million, a 15.7% increase year-over-year [2] - Definity maintained its market leadership in ultrasound-enhancing agents, generating fourth-quarter net sales of $86.2 million, up 17.9% year-over-year [4] Strategic Acquisitions - The company announced two acquisitions: Life Molecular Imaging, which will enhance its Alzheimer's disease diagnostics capabilities, and Evergreen Theragnostics, which will add a PET radiodiagnostic product [3] - Both acquisitions are expected to close in the second half of 2025 and could lead to multiple commercially approved products by 2026 [3] Financial Guidance - For 2025, the company estimates net revenue between $1.545 billion and $1.61 billion, reflecting a 1% to 5% increase over 2024, with expectations of low to mid-single-digit growth for both Pylarify and Definity [5] - The company anticipates generating $550 million to $600 million in free cash flow during 2025, which will support business development and share buybacks [5] Future Outlook - Management expressed confidence in the strategic direction and growth potential, focusing on expanding Pylarify and Definity while advancing the pipeline and completing the announced acquisitions [6]